892 results match your criteria: "Germany S.F.; Oxford University Hospitals Foundation NHS Trust[Affiliation]"

Fibroblast growth factor (FGF)-23 is a phosphaturic hormone. An association between increasing FGF-23 levels and progression of chronic kidney disease (CKD) was documented in cats, dogs, and humans. The information regarding reference intervals (RIs) of FGF-23 in cats is limited.

View Article and Find Full Text PDF

Protein Binder Toolbox for Studies of Solute Carrier Transporters.

J Mol Biol

August 2024

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria; Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria. Electronic address:

Transporters of the solute carrier superfamily (SLCs) are responsible for the transmembrane traffic of the majority of chemical substances in cells and tissues and are therefore of fundamental biological importance. As is often the case with membrane proteins that can be heavily glycosylated, a lack of reliable high-affinity binders hinders their functional analysis. Purifying and reconstituting transmembrane proteins in their lipidic environments remains challenging and standard approaches to generate binders for multi-transmembrane proteins, such as SLCs, channels or G protein-coupled receptors (GPCRs) are lacking.

View Article and Find Full Text PDF

Nocturnal hypoxemic burden and micro- and macrovascular disease in patients with type 2 diabetes.

Cardiovasc Diabetol

June 2024

Discipline of Biomedical Engineering, School of Electrical and Mechanical Engineering, University of Adelaide, North Terrace, Adelaide, SA, 5000, Australia.

Background: Micro- and macrovascular diseases are common in patients with type 2 diabetes mellitus (T2D) and may be partly caused by nocturnal hypoxemia. The study aimed to characterize the composition of nocturnal hypoxemic burden and to assess its association with micro- and macrovascular disease in patients with T2D.

Methods: This cross-sectional analysis includes overnight oximetry from 1247 patients with T2D enrolled in the DIACORE (DIAbetes COhoRtE) study.

View Article and Find Full Text PDF

Repair of the Infarcted Heart: Cellular Effectors, Molecular Mechanisms and Therapeutic Opportunities.

Circ Res

June 2024

Department of Medicine (Cardiology), The Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, Bronx, NY (N.G.F.).

The adult mammalian heart has limited endogenous regenerative capacity and heals through the activation of inflammatory and fibrogenic cascades that ultimately result in the formation of a scar. After infarction, massive cardiomyocyte death releases a broad range of damage-associated molecular patterns that initiate both myocardial and systemic inflammatory responses. TLRs (toll-like receptors) and NLRs (NOD-like receptors) recognize damage-associated molecular patterns (DAMPs) and transduce downstream proinflammatory signals, leading to upregulation of cytokines (such as interleukin-1, TNF-α [tumor necrosis factor-α], and interleukin-6) and chemokines (such as CCL2 [CC chemokine ligand 2]) and recruitment of neutrophils, monocytes, and lymphocytes.

View Article and Find Full Text PDF

Purpose: Optical coherence tomography (OCT) representations in clinical practice are static and do not allow for a dynamic visualization and quantification of blood flow. This study aims to present a method to analyze retinal blood flow dynamics using time-resolved structural OCT.

Methods: We developed novel imaging protocols to acquire video-rate time-resolved OCT B-scans (1024 × 496 pixels, 10 degrees field of view) at four different sensor integration times (integration time of 44.

View Article and Find Full Text PDF

Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.

N Engl J Med

August 2024

From the Departments of Pharmacology and Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes, University of Michigan Medical School, and the Endocrinology and Metabolism Section, Medicine Service, Lieutenant Colonel Charles S. Kettles Veterans Affairs Medical Center - both in Ann Arbor (R.J.A.); the Division of Endocrinology and Metabolism, University of Texas Southwestern Medical Center, Dallas (O.H.); Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Diabetologia, Andrologia e Nutrizione, Università Federico II di Napoli, Naples (R.P.), the Department of Pediatrics, Endocrine Unit, IRCCS San Raffaele Scientific Institute, Endo-ERN Center for Rare Endocrine Conditions, Milan (G.R.), and the Department of Experimental Medicine, Sapienza University of Rome, Rome (A.M.I.) - all in Italy; the Division of Endocrinology and Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester (I.B.), and the Departments of Pediatrics and Experimental and Clinical Pharmacology, Divisions of Endocrinology and Genetics and Metabolism, University of Minnesota Medical School, Minneapolis (K.S.) - both in Minnesota; the Division of Pediatric Endocrinology, Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh (S.F.W.); the Department of Endocrinology, Diabetology, and Nutrition, Endo-ERN Center for Rare Endocrine Conditions, Centre Hospitalier Universitaire d'Angers and Laboratoire Physiopathologie Cardiovasculaire et Mitochondriale, Université d'Angers, Angers, France (P.R.); the Departments of Endocrinology and Diabetes, University College London Hospital, London (U.S.); the Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna, Vienna (F.W.K.); the Department of Molecular Medicine and Surgery, Karolinska Institutet, and the Department of Endocrinology, Karolinska University Hospital, Stockholm (H.F.); the National Institutes of Health Clinical Center and Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (D.P.M.); the Department of Endocrinology, Internal Medicine IV, Ludwig Maximilians Universität München, Munich, Germany (N.R.); Gordon Cutler Consultancy, Deltaville, VA (G.B.C.); and Neurocrine Biosciences, San Diego, CA (J.S., E.R., V.H.L., J.L.C., R.H.F.).

Background: Adrenal insufficiency in patients with classic 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH) is treated with glucocorticoid replacement therapy. Control of adrenal-derived androgen excess usually requires supraphysiologic glucocorticoid dosing, which predisposes patients to glucocorticoid-related complications. Crinecerfont, an oral corticotropin-releasing factor type 1 receptor antagonist, lowered androstenedione levels in phase 2 trials involving patients with CAH.

View Article and Find Full Text PDF

Aspartate is crucial for nucleotide synthesis, ammonia detoxification, and maintaining redox balance via the malate-aspartate-shuttle (MAS). To disentangle these multiple roles of aspartate metabolism, tools are required that measure aspartate concentrations in real time and in live cells. We introduce AspSnFR, a genetically encoded green fluorescent biosensor for intracellular aspartate, engineered through displaying and screening biosensor libraries on mammalian cells.

View Article and Find Full Text PDF

Background: In the two European Union (EU)-funded projects, PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials), we aim to facilitate implementation of precision cancer medicine (PCM) in Europe by leveraging the experience from ongoing national initiatives that have already been particularly successful.

Patients And Methods: PCM4EU and PRIME-ROSE gather 17 and 24 partners, respectively, from 19 European countries. The projects are based on a network of Drug Rediscovery Protocol (DRUP)-like clinical trials that are currently ongoing or soon to start in 11 different countries, and with more trials expected to be established soon.

View Article and Find Full Text PDF

Among the most common genetic alterations in myelodysplastic syndromes (MDS) are mutations in the spliceosome gene SF3B1. Such mutations induce specific RNA missplicing events, directly promote ring sideroblast (RS) formation, and generally associate with a more favorable prognosis. However, not all SF3B1 mutations are the same, and little is known about how distinct hotspots influence disease.

View Article and Find Full Text PDF

The κ-(P,N)-phosphine ligand precursor NH(CHCHPCy) can be used for the synthesis of the rhodium(I) complex [Rh(CO){ĸ-(P,N,P)-CyPCHNHCHPCy}][Cl] (1). The deprotonated complex [Rh(CO){ĸ-(P,N,P)-CyPCHNCHPCy}] (2) shows a cooperative reactivity of the PNP ligand in the activation reaction of SOF to yield the rhodium fluorido complex trans-[Rh(F)(CO){ĸ-(P,P)-CyPCHN(SOF)CHPCy}] (3) by S-F bond cleavage. It is remarkable that no reaction was observed when 3 was treated with hydrogen sources e.

View Article and Find Full Text PDF

Background: Whether hemorrhagic transformation (HT) modifies the treatment effect of early compared with late initiation of direct oral anticoagulation in people with ischemic stroke and atrial fibrillation is unknown.

Methods: This is a post hoc analysis of the ELAN trial (Early Versus Late Initiation of Direct Oral Anticoagulants in Post-Ischaemic Stroke Patients With Atrial Fibrillation). The primary outcome was a composite of recurrent ischemic stroke, symptomatic intracranial hemorrhage, major extracranial bleeding, systemic embolism, or vascular death within 30 days.

View Article and Find Full Text PDF

Background: Studies comparing bridging intravenous thrombolysis (IVT) with direct endovascular therapy (EVT) in patients with acute ischemic stroke who present late are limited. We aimed to compare the clinical outcomes and safety of bridging IVT in patients with acute ischemic stroke due to anterior circulation large vessel occlusion who underwent EVT 6 to 24 hours after time last known well.

Methods: We enrolled patients with anterior circulation large vessel occlusion stroke and a National Institutes of Health Stroke Scale score of ≥6 from 20 centers across 10 countries in the multicenter retrospective CLEAR study (CT for Late Endovascular Reperfusion) between January 2014 and May 2022.

View Article and Find Full Text PDF

Purpose: Multiple clinical visits are necessary to determine progression of keratoconus before offering corneal cross-linking. The purpose of this study was to develop a neural network that can potentially predict progression during the initial visit using tomography images and other clinical risk factors.

Methods: The neural network's development depended on data from 570 keratoconus eyes.

View Article and Find Full Text PDF

Pacemaker Channels and the Chronotropic Response in Health and Disease.

Circ Res

May 2024

Institute of Cardiovascular Physiology and Pathophysiology, Biomedical Center Munich, Walter Brendel Centre of Experimental Medicine, Faculty of Medicine (K.H., C.P., C.W.-S.), Ludwig-Maximilians-Universität München, Germany.

Loss or dysregulation of the normally precise control of heart rate via the autonomic nervous system plays a critical role during the development and progression of cardiovascular disease-including ischemic heart disease, heart failure, and arrhythmias. While the clinical significance of regulating changes in heart rate, known as the chronotropic effect, is undeniable, the mechanisms controlling these changes remain not fully understood. Heart rate acceleration and deceleration are mediated by increasing or decreasing the spontaneous firing rate of pacemaker cells in the sinoatrial node.

View Article and Find Full Text PDF

We report the superconducting properties of Co/Pb/Co heterostructures with thin insulating interlayers. The main specific feature of these structures is the intentional oxidation of both superconductor/ferromagnet (S/F) interfaces. We study the variation of the critical temperature of our systems due to switching between parallel and antiparallel configurations of the magnetizations of the two magnetic layers.

View Article and Find Full Text PDF

Background And Aims: Acute ischemic stroke (AIS) outcome prognostication remains challenging despite available prognostic models. We investigated whether a biomarker panel improves the predictive performance of established prognostic scores.

Methods: We investigated the improvement in discrimination, calibration, and overall performance by adding five biomarkers (procalcitonin, copeptin, cortisol, mid-regional pro-atrial natriuretic peptide (MR-proANP), and N-terminal pro-B-type natriuretic peptide (NT-proBNP)) to the Acute Stroke Registry and Analysis of Lausanne (ASTRAL) and age/NIHSS scores using data from two prospective cohort studies (SICFAIL, PREDICT) and one clinical trial (STRAWINSKI).

View Article and Find Full Text PDF

A transdiagnostic prodrome for severe mental disorders: an electronic health record study.

Mol Psychiatry

November 2024

Early Psychosis: Interventions and Clinical-Detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, SE5 8AF, UK.

Effective prevention of severe mental disorders (SMD), including non-psychotic unipolar mood disorders (UMD), non-psychotic bipolar mood disorders (BMD), and psychotic disorders (PSY), rely on accurate knowledge of the duration, first presentation, time course and transdiagnosticity of their prodromal stages. Here we present a retrospective, real-world, cohort study using electronic health records, adhering to RECORD guidelines. Natural language processing algorithms were used to extract monthly occurrences of 65 prodromal features (symptoms and substance use), grouped into eight prodromal clusters.

View Article and Find Full Text PDF

Noncontrast CT Selected Thrombectomy vs Medical Management for Late-Window Anterior Large Vessel Occlusion.

Neurology

May 2024

From the Department of Neurology (T.N.N., P.K., Z.M.), and Department of Radiology (T.N.N., M.M.Q., M.A., P.K., Z.M.), Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, MA; Department of Neurology (R.G.N.), Neurosurgery, University of Pittsburgh Medical Center, PA; Department of Radiation Oncology (M.M.Q.), Boston Medical Center, MA; Department of Neurology (S. Nagel), Klinikum Ludwigshafen, Ludwigshafen, Germany; Department of Neurology (S. Nagel, P.A.R.), Heidelberg University Hospital, Germany; Interventional Neuroradiology Laboratory (J.R., D.R.), Department of Radiology, Centre Hospitalier de l'Universite de Montreal, Quebec, Canada; Department of Neurology (J.D., L.V., A.W., R.L.), UZ Leuven; Laboratory for Neurobiology (J.D., L.V., A.W., R.L.), KU Leuven, Belgium; Department of Neurology (J.P.M., R.V.), Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Portugal; Department of Neurology (S.A.S., S.S.-M.), UTHealth McGovern Medical School, Houston, TX; Department of Neurology (V.P., S.W.), and Dresden Neurovascular Center (V.P., S.W., D.P.O.K.), Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; Department of Neurology (A.D., F.B.), Hôpital Civil Marie Curie, Charleroi, Belgium; Department of Neurology (P.M., D. Strambo), Lausanne University Hospital and University of Lausanne, Switzerland; Department of Neurology (M. Ribo, M.O.-G., M. Requena), Hospital Vall d'Hebron, Barcelona, Spain; Neuroscience and Stroke Program (O.O.Z., E.L.), Bon Secours Mercy Health St. Vincent Hospital, Toledo, OH; Department of Neurology (J.E.S.), University of Chicago, IL; Department of Neurology (D.C.H., M.H.M.), Grady Memorial Hospital, Atlanta, GA; Department of Neurology (D. Strbian, L.T., N.M.-M.), Helsinki University Hospital, University of Helsinki, Finland; Department of Neurology (H.H., F.C., C.C.), Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Lille, France; Department of Radiology (M.A.M., J.J.), Heidelberg University Hospital, Germany; Division of Interventional Neuroradiology (A.S.P.), University of Massachusetts Memorial Medical Center, Worcester; Department of Diagnostic and Interventional Neuroradiology (J.K., A.M.), University Hospital Bern, Switzerland; Department of Radiology (J.N.R.), Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Portugal; Department of Neurology (M.A.J., S.F.Z., A.C.C.), University of Toledo, OH; Department of Clinical Neurosciences (S. Nannoni), University of Cambridge, United Kingdom; Department of Neurology (M.F., S.O.-G.), University of Iowa, Iowa City; Department of Radiology (P.V., E.P.), Helsinki University Hospital, University of Helsinki, Finland; Institute of Neuroradiology (D.P.O.K.), Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; Department of Neurology (L.S., S.Y.), Rhode Island Hospital, Providence; Department of Neurology (Z.Q.), 903rd Hospital of The Chinese People's Liberation Army, Hangzhou, China; Department of Neurology (H.E.M.), State University of New York, Syracuse; Department of Neurology (W.H.), The First Affiliated Hospital of USTC, China; Department of Cerebrovascular Medicine (K.T.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Stroke Neurology (H.Y.), NHO Osaka National Hospital, Japan; Department of Neurology (U.F.), University Hospital Basel, Switzerland; Department of Neurology (U.F.), University Hospital Bern, Switzerland; and Department of Neurology (T.G.J.), Cooper University Hospital, Camden, NJ.

Background And Objectives: There is uncertainty whether patients with large vessel occlusion (LVO) presenting in the late 6-hour to 24-hour time window can be selected for endovascular therapy (EVT) by noncontrast CT (NCCT) and CT angiography (CTA) for LVO detection. We evaluated the clinical outcomes of patients selected for EVT by NCCT compared with those medically managed in the extended time window.

Methods: This multinational cohort study was conducted at 66 sites across 10 countries.

View Article and Find Full Text PDF

Survey of Pharmaceutical Industry's Best Practices around In Vitro Transporter Assessment and Implications for Drug Development: Considerations from the International Consortium for Innovation and Quality for Pharmaceutical Development Transporter Working Group.

Drug Metab Dispos

June 2024

Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (H.E.R., K.S.F.); Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut (P.M., M.T.); Quantitative Clinical Pharmacology, Development Sciences, UCB Biopharma SRL, Braine-L'Alleud, Belgium (H.C.); NCE Drug Metabolism and Pharmacokinetics, the healthcare business of Merck KGaA, Darmstadt, Germany (Z.F.); Drug Metabolism, Gilead Sciences, Inc. Foster City, California (X.L., Y.L.); Preclinical Sciences and Translational Safety, Janssen R&D LLC, Spring House, Pennsylvania (S.H.P.); Pharmacokinetics, Dynamics and Metabolism, Medicine Design, Worldwide R&D, Pfizer Inc, Groton, Connecticut (C.C.); Pharmacokinetic Sciences, Novartis Institutes for Biomedical Research, East Hanover, New Jersey (I.H.); Clinical Pharmacology Modelling and Simulations, GlaxoSmithKline Research and Development, Collegeville, Pennsylvania (N.T., K.M.M.); IQ Secretariat, Faegre Drinker Biddle & Reath, LLP., Washington DC (J.M.V.); Quantitative, Translational and ADME Sciences, AbbVie Inc., North Chicago, Illinois (D.A.J.B.); Investigative Drug Disposition, Lilly Research Laboratories, Eli Lilly Inc, Indianapolis, Indiana (K.M.H.); Nonclinical Biostatistics, Genentech, Inc., South San Francisco, California (J.B.); ADME and Discovery Toxicity, Merck & Co., Inc., Rahway, New Jersey (X.C.); Departments of Drug Metabolism and Pharmacokinetics (C.E.C.A.H., L.S.) and Clinical Pharmacology (R.S.), Genentech, Inc., South San Francisco, California; Department of Pharmacokinetics and Drug Metabolism, Amgen Inc. South San Francisco, California (C.Y.L.); Department of Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb Research and Development, Princeton, New Jersey (H.S.); DMPK Modeling, IVIVT, Research, GSK, Stevenage, United Kingdom (Ku.T.); Takeda Pharmaceutical Company Limited, Fujisawa, Japan (Ki.T.); and Pharmacokinetics, Dynamics, and Metabolism, Translational Medicine and Early Development, Sanofi US, Bridgewater, NJ (C.X.).

The International Consortium for Innovation and Quality in Pharmaceutical Development Transporter Working Group had a rare opportunity to analyze a crosspharma collation of in vitro data and assay methods for the evaluation of drug transporter substrate and inhibitor potential. Experiments were generally performed in accordance with regulatory guidelines. Discrepancies, such as not considering the impact of preincubation for inhibition and free or measured in vitro drug concentrations, may be due to the retrospective nature of the dataset and analysis.

View Article and Find Full Text PDF

Positron emission tomography (PET) is a powerful imaging technique for biomedical research, drug development and medical diagnosis. The power of PET lies in biochemically selective radiotracers, labelled with positron emitters like fluorine-18 image chemical processes in vivo. A rapid and remarkably efficient, unprecedented protocol to select between S-F and C-F bond formation based on activation of 1,1-difluoroethylene groups followed by selective oxidation or reduction is described.

View Article and Find Full Text PDF

Recommendations on fit-for-purpose criteria to establish quality management for microphysiological systems and for monitoring their reproducibility.

Stem Cell Reports

May 2024

CAAT Europe, University of Konstanz, Konstanz, Germany; In vitro Toxicology and Biomedicine, Department inaugurated by the Doerenkamp-Zbinden foundation, University of Konstanz, Konstanz, Germany.

Cell culture technology has evolved, moving from single-cell and monolayer methods to 3D models like reaggregates, spheroids, and organoids, improved with bioengineering like microfabrication and bioprinting. These advancements, termed microphysiological systems (MPSs), closely replicate tissue environments and human physiology, enhancing research and biomedical uses. However, MPS complexity introduces standardization challenges, impacting reproducibility and trust.

View Article and Find Full Text PDF

Antibody features vary with tuberculosis (TB) disease state. Whether clinical variables, such as age or sex, influence associations between Mycobacterium tuberculosis-specific antibody responses and disease state is not well explored. Here we profiled Mycobacterium tuberculosis-specific antibody responses in 140 TB-exposed South African individuals from the Adolescent Cohort Study.

View Article and Find Full Text PDF

Study of the f_{0}(980) and f_{0}(500) Scalar Mesons through the Decay D_{s}^{+}→π^{+}π^{-}e^{+}ν_{e}.

Phys Rev Lett

April 2024

State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China.

Using e^{+}e^{-} collision data corresponding to an integrated luminosity of 7.33  fb^{-1} recorded by the BESIII detector at center-of-mass energies between 4.128 and 4.

View Article and Find Full Text PDF

Metastatic Breast Cancer: Prolonging Life in Routine Oncology Care.

Cancers (Basel)

March 2024

Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitaetsmedizin Mainz, 55131 Mainz, Germany.

Overall survival (OS) of patients with metastatic breast cancer (MBC) has improved within controlled clinical trials. Whether these advances translate into improved OS in routine care is controversial. We therefore analyzed retrospectively unselected female patients from five oncology group practices and one university outpatient clinic, whose initial diagnosis of MBC was between 1995 and 2022.

View Article and Find Full Text PDF

Excited-State Lifetime of NV Centers for All-Optical Magnetic Field Sensing.

Sensors (Basel)

March 2024

Department of Electrical Engineering and Computer Science, FH Münster-University of Applied Sciences, Stegerwaldstr. 39, 48565 Steinfurt, Germany.

We investigate the magnetic field-dependent fluorescence lifetime of microdiamond powder containing a high density of nitrogen-vacancy centers. This constitutes a non-intensity quantity for robust, all-optical magnetic field sensing. We propose a fiber-based setup in which the excitation intensity is modulated in a frequency range up to 100MHz.

View Article and Find Full Text PDF